科兴制药
(688136)
| 流通市值：46.23亿 | | | 总市值：46.23亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 607,123,999.5 | 280,525,124.96 | 1,534,028,363.15 | 1,147,639,140.97 |
| 营业总成本 | 707,017,745.88 | 300,163,833.04 | 1,479,489,096.16 | 1,070,420,698.89 |
| 其他经营收益 | | | | |
| 营业利润 | 146,583,435.88 | -25,691,090.37 | 168,110,667.57 | 117,673,761.91 |
| 利润总额 | 147,061,716.4 | -25,834,096.17 | 165,699,363.49 | 115,338,711.46 |
| 净利润 | 132,477,247.74 | -18,553,838.47 | 152,744,259.08 | 109,102,136.34 |
| 每股收益 | | | | |
| 其他综合收益 | -231,677.93 | 263,706.13 | -180,713.14 | -80,087.15 |
| 综合收益总额 | 132,245,569.81 | -18,290,132.34 | 152,563,545.94 | 109,022,049.19 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,507,291,580.57 | 1,553,201,910.63 | 1,607,355,795.91 | 1,550,078,576.41 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,204,797,146.57 | 1,937,236,091.4 | 1,926,199,354.36 | 1,861,242,018.72 |
| 资产总计 | 3,712,088,727.14 | 3,490,438,002.03 | 3,533,555,150.27 | 3,411,320,595.13 |
| 流动负债: | | | | |
| 流动负债合计 | 1,121,038,366.3 | 1,037,150,463.1 | 1,021,257,003.8 | 1,032,648,614.83 |
| 非流动负债: | | | | |
| 非流动负债合计 | 753,203,839.67 | 724,637,559.1 | 759,791,779.87 | 662,546,077.37 |
| 负债合计 | 1,874,242,205.97 | 1,761,788,022.2 | 1,781,048,783.67 | 1,695,194,692.2 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,837,797,255.03 | 1,727,752,628.81 | 1,750,991,742.17 | 1,713,948,639.84 |
| 股东权益合计 | 1,837,846,521.17 | 1,728,649,979.83 | 1,752,506,366.6 | 1,716,125,902.93 |
| 负债和股东权益合计 | 3,712,088,727.14 | 3,490,438,002.03 | 3,533,555,150.27 | 3,411,320,595.13 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 718,479,310.72 | 346,684,814 | 1,398,636,678.96 | 929,454,734.91 |
| 经营活动现金流出小计 | 693,233,665.54 | 339,767,384.49 | 1,312,607,793.17 | 936,712,263.1 |
| 经营活动产生的现金流量净额 | 25,245,645.18 | 6,917,429.51 | 86,028,885.79 | -7,257,528.19 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 325,677,779.39 | 287,967,761.58 | 1,794,474,172.22 | 1,362,838,531.45 |
| 投资活动现金流出小计 | 456,631,866.95 | 326,322,293.84 | 1,858,236,114.82 | 1,518,701,955.76 |
| 投资活动产生的现金流量净额 | -130,954,087.56 | -38,354,532.26 | -63,761,942.6 | -155,863,424.31 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 387,534,057.7 | 143,900,000 | 935,799,708.76 | 729,011,188.76 |
| 筹资活动现金流出小计 | 432,551,289.29 | 163,060,610.33 | 862,485,611.85 | 628,626,263.6 |
| 筹资活动产生的现金流量净额 | -45,017,231.59 | -19,160,610.33 | 73,314,096.91 | 100,384,925.16 |
| 汇率变动对现金及现金等价物的影响 | -4,631,923.51 | -2,536,495.53 | -210,761.57 | 786,051.79 |
| 现金及现金等价物净增加额 | -155,357,597.48 | -53,134,208.61 | 95,370,278.53 | -61,949,975.55 |
| 期末现金及现金等价物余额 | 492,964,623.64 | 595,188,012.51 | 648,322,221.12 | 491,001,967.04 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -155,357,597.48 | - | 95,370,278.53 | - |